[{"id":"3174eb09-547d-4053-9bb7-a8326b4fcbac","acronym":"","url":"https://clinicaltrials.gov/study/NCT03841617","created_at":"2021-07-05T17:20:24.574Z","updated_at":"2025-02-25T12:27:07.917Z","phase":"Phase 2","brief_title":"The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03841617","lead_sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","biomarkers":" BRAF • TG","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/29/2019","start_date":" 07/29/2019","primary_txt":" Primary completion: 02/01/2030","primary_completion_date":" 02/01/2030","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2025-02-24"},{"id":"2cfcde7a-d491-42b2-9d06-8123de42c77d","acronym":"A091302","url":"https://clinicaltrials.gov/study/NCT02143726","created_at":"2021-09-08T20:53:26.218Z","updated_at":"2025-02-25T15:41:37.517Z","phase":"Phase 2","brief_title":"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","source_id_and_acronym":"NCT02143726 - A091302","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/09/2014","start_date":" 10/09/2014","primary_txt":" Primary completion: 01/28/2021","primary_completion_date":" 01/28/2021","study_txt":" Completion: 08/06/2028","study_completion_date":" 08/06/2028","last_update_posted":"2025-01-27"},{"id":"0f2198ed-12a6-4300-b49a-f4eb9638b583","acronym":"","url":"https://clinicaltrials.gov/study/NCT06367010","created_at":"2024-04-16T14:31:25.387Z","updated_at":"2024-07-02T16:35:09.496Z","phase":"","brief_title":"Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients","source_id_and_acronym":"NCT06367010","lead_sponsor":"Jiangxi Provincial Cancer Hospital","biomarkers":" CEACAM5 • TG","pipe":"","alterations":" ","tags":["CEACAM5 • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-04-16"},{"id":"4e1f0628-5e42-4120-a139-7a20f3dbe753","acronym":"","url":"https://clinicaltrials.gov/study/NCT06362772","created_at":"2024-04-12T13:45:08.667Z","updated_at":"2024-07-02T16:35:09.978Z","phase":"","brief_title":"Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer","source_id_and_acronym":"NCT06362772","lead_sponsor":"Jiangxi Provincial Cancer Hospital","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2024-04-12"},{"id":"5c9414e8-7220-42f4-8441-a2cd65e87bf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05463107","created_at":"2022-07-18T14:01:53.359Z","updated_at":"2024-07-02T16:35:14.098Z","phase":"","brief_title":"Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer","source_id_and_acronym":"NCT05463107","lead_sponsor":"National Taiwan University Hospital","biomarkers":" KRT19 • KRT8 • TG","pipe":"","alterations":" ","tags":["KRT19 • KRT8 • TG"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2024-03-19"},{"id":"fe01e886-d4e1-4741-8820-8d1c79291a4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06154863","created_at":"2023-12-04T19:28:11.350Z","updated_at":"2024-07-02T16:35:18.971Z","phase":"","brief_title":"Recurrence in Patients With Differentiated Thyroid Cancer","source_id_and_acronym":"NCT06154863","lead_sponsor":"Assiut University","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-02-19"},{"id":"d6544d5c-22e0-428e-b270-2a60bc0e02bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447183","created_at":"2021-01-18T21:23:59.877Z","updated_at":"2024-07-02T16:35:32.204Z","phase":"Phase 2","brief_title":"The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.","source_id_and_acronym":"NCT04447183","lead_sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e recombinant human thyroid stimulating hormone for injection (rhTSH)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-23"},{"id":"cd0f6606-7994-4a73-a495-0a49c28f1d77","acronym":"RESET","url":"https://clinicaltrials.gov/study/NCT04858867","created_at":"2021-04-26T12:52:42.632Z","updated_at":"2024-07-02T16:35:34.200Z","phase":"","brief_title":"Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)","source_id_and_acronym":"NCT04858867 - RESET","lead_sponsor":"Leiden University Medical Center","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 01/10/2022","start_date":" 01/10/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-09"},{"id":"6297da7e-a541-467f-90e8-26e1b4cd9df3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06051838","created_at":"2023-09-25T14:10:20.418Z","updated_at":"2024-07-02T16:35:35.879Z","phase":"","brief_title":"Prognostic Value of Tumor Deposits for Patients With Papillary Thyroid Carcinoma","source_id_and_acronym":"NCT06051838","lead_sponsor":"Nanfang Hospital, Southern Medical University","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"],"overall_status":"Completed","enrollment":" Enrollment 541","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2023-09-25"},{"id":"65ee4aeb-1d5e-40c8-b4fd-071957df07fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02347683","created_at":"2023-09-05T21:09:20.725Z","updated_at":"2024-07-02T16:35:38.140Z","phase":"","brief_title":"Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy","source_id_and_acronym":"NCT02347683","lead_sponsor":"University of Nebraska","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2023-09-04"},{"id":"c80cf134-c02c-4a93-8bf8-d4cdb0927440","acronym":"","url":"https://clinicaltrials.gov/study/NCT05175404","created_at":"2022-01-03T15:00:45.734Z","updated_at":"2024-07-02T16:35:39.052Z","phase":"Phase 2","brief_title":"Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers","source_id_and_acronym":"NCT05175404","lead_sponsor":"University Hospital, Ghent","biomarkers":" TG","pipe":" | ","alterations":" FOLH1 expression","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 01/24/2022","start_date":" 01/24/2022","primary_txt":" Primary completion: 07/18/2023","primary_completion_date":" 07/18/2023","study_txt":" Completion: 07/18/2023","study_completion_date":" 07/18/2023","last_update_posted":"2023-08-24"},{"id":"5b7d2ed5-ea8c-4aab-947b-9586e9917bb0","acronym":"INSPIRE","url":"https://clinicaltrials.gov/study/NCT04391244","created_at":"2023-04-19T22:03:51.012Z","updated_at":"2024-07-02T16:35:39.773Z","phase":"","brief_title":"Investigating National Solutions for Personalised Iodine-131 Radiation Exposure","source_id_and_acronym":"NCT04391244 - INSPIRE","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/17/2020","start_date":" 06/17/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-08-17"},{"id":"ea259fb5-3f93-4045-aa2d-a83218c93202","acronym":"","url":"https://clinicaltrials.gov/study/NCT01141309","created_at":"2021-01-18T04:32:19.305Z","updated_at":"2024-07-02T16:35:42.533Z","phase":"Phase 2","brief_title":"Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer","source_id_and_acronym":"NCT01141309","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PTEN • TG","pipe":" | ","alterations":" PTEN mutation • MTOR mutation","tags":["PTEN • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-19"},{"id":"53537bf3-eae7-42ad-947c-fe82b3ec3eae","acronym":"ERRITI","url":"https://clinicaltrials.gov/study/NCT04619316","created_at":"2021-01-19T20:34:09.715Z","updated_at":"2024-07-02T16:35:45.180Z","phase":"Phase 2","brief_title":"Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition","source_id_and_acronym":"NCT04619316 - ERRITI","lead_sponsor":"University Hospital, Essen","biomarkers":" TG","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-06-22"},{"id":"731ec488-76d5-4840-bef3-4f848d9f7c7c","acronym":"ITCO","url":"https://clinicaltrials.gov/study/NCT04031339","created_at":"2021-01-18T19:47:07.177Z","updated_at":"2024-07-02T16:35:48.395Z","phase":"","brief_title":"Study of Clinical Outcomes of Thyroid Cancer","source_id_and_acronym":"NCT04031339 - ITCO","lead_sponsor":"University of Roma La Sapienza","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"],"overall_status":"Recruiting","enrollment":" Enrollment 15000","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-05-10"},{"id":"522b2880-fdc3-457c-bd7e-d2a0eb1974f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05668962","created_at":"2022-12-30T14:58:34.811Z","updated_at":"2024-07-02T16:35:50.690Z","phase":"Phase 2","brief_title":"Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC","source_id_and_acronym":"NCT05668962","lead_sponsor":"Massachusetts General Hospital","biomarkers":" RET • TG","pipe":" | ","alterations":" RET fusion","tags":["RET • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-04-13"},{"id":"2e2eca56-d2c6-4ba6-84f4-22cb6d82234a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02393690","created_at":"2021-01-18T11:24:58.815Z","updated_at":"2024-07-02T16:35:56.531Z","phase":"Phase 2","brief_title":"Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02393690","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/04/2015","start_date":" 05/04/2015","primary_txt":" Primary completion: 07/17/2020","primary_completion_date":" 07/17/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-02"},{"id":"4953a1bf-5abc-4d0f-a83c-e35443af9380","acronym":"","url":"https://clinicaltrials.gov/study/NCT04948437","created_at":"2021-07-02T12:52:35.475Z","updated_at":"2024-07-02T16:36:02.236Z","phase":"","brief_title":"Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer","source_id_and_acronym":"NCT04948437","lead_sponsor":"National Taiwan University Hospital","biomarkers":" KRT19 • KRT8 • TG","pipe":"","alterations":" ","tags":["KRT19 • KRT8 • TG"],"overall_status":"Recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 08/19/2021","start_date":" 08/19/2021","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2022-10-18"},{"id":"1db27810-1326-4d7c-a744-d511488d5c3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05466812","created_at":"2022-07-20T12:56:24.373Z","updated_at":"2024-07-02T16:36:07.138Z","phase":"Phase 4","brief_title":"Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases","source_id_and_acronym":"NCT05466812","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 07/13/2024","primary_completion_date":" 07/13/2024","study_txt":" Completion: 07/13/2025","study_completion_date":" 07/13/2025","last_update_posted":"2022-07-20"},{"id":"c0fb26e4-588f-4ea3-80da-f8b88b7324e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02702388","created_at":"2021-07-05T16:52:02.815Z","updated_at":"2025-02-25T16:04:25.407Z","phase":"Phase 2","brief_title":"A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile","source_id_and_acronym":"NCT02702388","lead_sponsor":"Eisai Inc.","biomarkers":" FGF23 • TG","pipe":"","alterations":" ","tags":["FGF23 • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 241","initiation":"Initiation: 06/08/2017","start_date":" 06/08/2017","primary_txt":" Primary completion: 12/12/2019","primary_completion_date":" 12/12/2019","study_txt":" Completion: 09/10/2020","study_completion_date":" 09/10/2020","last_update_posted":"2021-11-24"},{"id":"868f20e2-cb59-435e-8f2a-4edb23b8dd9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01208051","created_at":"2021-01-18T04:50:33.670Z","updated_at":"2024-07-02T16:36:27.878Z","phase":"Phase 1/2","brief_title":"Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer","source_id_and_acronym":"NCT01208051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • RAS • TG","pipe":" | ","alterations":" RAS mutation","tags":["BRAF • RAS • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 09/09/2010","start_date":" 09/09/2010","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2021-07-15"},{"id":"beafe807-5a78-4bd5-ba5e-40d252bfd50e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04554680","created_at":"2021-01-18T21:46:28.506Z","updated_at":"2024-07-02T16:36:33.733Z","phase":"Phase 2","brief_title":"Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF \u0026 MEK Blockade for Re-differentiation Therapy","source_id_and_acronym":"NCT04554680","lead_sponsor":"National University Hospital, Singapore","biomarkers":" TG","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • RAS mutation","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2021-03-05"},{"id":"0c01e506-c86f-429d-b796-895cfd2288e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02138214","created_at":"2021-09-08T20:53:24.305Z","updated_at":"2024-07-02T16:36:37.061Z","phase":"Phase 2","brief_title":"Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer","source_id_and_acronym":"NCT02138214","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 06/06/2014","start_date":" 06/06/2014","primary_txt":" Primary completion: 10/30/2019","primary_completion_date":" 10/30/2019","study_txt":" Completion: 10/26/2020","study_completion_date":" 10/26/2020","last_update_posted":"2020-12-21"},{"id":"6c411848-b04a-442c-8d21-43af22db1e52","acronym":"","url":"https://clinicaltrials.gov/study/NCT03271892","created_at":"2021-01-18T16:09:38.778Z","updated_at":"2024-07-02T16:36:40.746Z","phase":"","brief_title":"Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer","source_id_and_acronym":"NCT03271892","lead_sponsor":"University Health Network, Toronto","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 05/11/2016","start_date":" 05/11/2016","primary_txt":" Primary completion: 05/11/2026","primary_completion_date":" 05/11/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2020-09-24"}]